From NICE above.
'Populations
People who have had non-cardioembolic ischaemic stroke or transient
ischaemic attack for whom clopidogrel treatment is being considered.
Where data permits, the following subgroups may be considered:
• People of different ethnicities
• People with different severity of stroke (TIA, moderate or severe ischaemic
stroke)
• People who would receive clopidogrel earlier than 2 weeks after onset of
symptoms
• Children and young people.'
H |
From memory the stroke test is beneficial to people of a certain background, in that our DNA has a family reference, and a higher incidence in this particular case of needing a different medication to benefit.
Now where did I read that?
IMO |
Hey!
The Middle East!
'In just 1 WEEK, Genedrive are exhibiting at MedlabMiddle East!
Visit stand Z2.K11 to discover our innovative pharmacogenetic testing products.
Contact enquiries@genedrive.com to book a meeting.' |
Thank goodness for some good research and sensible posting. |
False rise for the purpose of a placing |
Further news this time will skyrocket these shares way past 5p |
I see the pathetic troll jailbird is posting his garbage on the other thread
The idiot was probably waiting to buy , but the price took off yesterday so hence his deramps hahaha
Hey troll short term target is 4p to 5p.
Hope that helps you |
PBJust be wary of cash call now.See what the strike price will be |
Ah ok thats an interesting one Interests me as my dad had a TIA and is on clopidogrelMarket there for this one |
Gone NT to buy even 25,000 @ 2.35p |
I'm holding to hit that top of the bowl at 10p. |
The price has fallen from 5p after CYP2C19 was approved in July 2024.
Share price will rerate abck that level over the coming days/weeks.
The valuation is just far too LOW. |
Meanwhile it's begging to break out of this range. Won't be long now. |
It's not about the deafness product, it's all about the stroke one, that's where the money is. |
Jailbird, read about their CYP2C-19 test for guiding clopidogrel (see RNS news announcements). |
USA is the market it needs to target . Early days there yet 370k are born prematurely , so there is a decent number even though not mind blowing It is gonna take quite a bit of time here , so I will pass here for now . Will keep one eye on it though Good luck all |
I'd suggest some further research if you are genuinely interested in investing in the company.
hxxps://www.genedriveplc.com/news/press-releases.php |
PBAccording to the website , under About us The only offering is the kit for neonatal And I just do not see the market is big enough , it will need to prove and develop its product for use on wider population ages and other types of health issues associated regardless of age |
Could be news any time.
Let's face it it has come on in leaps and bounds.
It's only the share price that needs to wake up! |
Hi Jailbird - ignore the birdbrain above, there is active conversation on here regarding the company and its prospects.
There are other products that are more likely to drive profits than the test you mention - I suggest you read up if interested genuinely, and not just here because you saw a mindless ramp elsewhere.
A cash call likely without further progress in sales, my expectation is that this will be done in conjunction with an partnership or major sales agreement, however this isn't based on anything concrete. At 2p the shares have priced much of this in, a 2p downside and ridiculous upside is what interests me here, the risk/reward is excellent.
IndianGod just a frustrated child who needs to stop masterbating, it's making him angry. |
The promoters on this board don't like anybody talking about the company's cash position. I wonder why. |
Ok found more info According to information from NICE (National Institute for Health and Care Excellence), the Genedrive MT-RNR1 ID Kit costs approximately £100 (excluding VAT) per test. Key points about the Genedrive MT-RNR1 Kit:Purpose: Used to detect a specific genetic variant (m.1555A>G) in the mitochondrial RNR1 gene, which can help guide antibiotic treatment decisions in babies to prevent hearing loss.Cost per test: £100 (excluding VAT)Important consideration: The overall cost of using the kit may include additional factors like the cost of the Genedrive machine, staff costs, and control tests |
Hello all As Zico mentioned this on another thread ,Thought I have a look at the fundamentals No agenda here, just wanting thoughts Cash is due to run out in April So expected them raise another years cash At 2p that will take the shares in issue to approx 1 billion, market will be approx £20mWith only Middle East and UK markets having potential revenue offerings at present Do you expect in can make enough revenues to become cashflow positive?I just think they need to sell this to the bigger markets like while of EU and USA toMake decent money I am not sure what each kit sells |
The sooner this stock delists the better |
Register to chat with like-minded investors on our interactive forums.
Hot Features
Premium
